规格 | 目录价格 | 上海 | 安徽 | 武汉 | 成都 | 北方 | 深圳 | 会员价格 | 数量 |
---|---|---|---|---|---|---|---|---|---|
mg | ¥ ȍƿŞĸƬƬ | -- | -- | -- | -- | -- | -- | ¥ ȍƿŞĸƬƬ | - + |
10mg | ¥ ŶƬƬĸƬƬ | -- | -- | -- | -- | -- | -- | ¥ ŶƬƬĸƬƬ | - + |
2mg | ¥ ǼǼƬĸƬƬ | -- | -- | -- | -- | -- | -- | ¥ ǼǼƬĸƬƬ | - + |
0mg | ¥ ȍƬƉƬĸƬƬ | -- | -- | -- | -- | -- | -- | ¥ ȍƬƉƬĸƬƬ | - + |
100mg | ¥ ȍǼƿƬĸƬƬ | -- | -- | -- | -- | -- | -- | ¥ ȍǼƿƬĸƬƬ | - + |
200mg | ¥ ĒǼƿƬĸƬƬ | -- | -- | -- | -- | -- | -- | ¥ ĒǼƿƬĸƬƬ | - + |
00mg | ¥ ƉǼŶƬĸƬƬ | -- | -- | -- | -- | -- | -- | ¥ ƉǼŶƬĸƬƬ | - + |
1g | 请询价 | -- | -- | -- | -- | -- | -- | -- | - + |
g | 请询价 | -- | -- | -- | -- | -- | -- | -- | - + |
10g | 请询价 | -- | -- | -- | -- | -- | -- | -- | - + |
139.4
[1]. Imamura M, et al. Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus. Bioorg Med Chem. 2012 May 1;20(10):323-79.
[2]. Suzuki M, et al. Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice. J Pharmacol Exp Ther. 2012 Jun;341(3):92-701.
[3]. Tahara A, et al. Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin-nicotinamide-induced mildly diabetic mice. J Pharmacol Sci. 2012;120(1):3-44.
[4]. Tahara A, et al. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur J Pharmacol. 2013 Sep ;71(1-3):24-.
[]. Tahara A, et al. Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo. Naunyn Schmiedebergs Arch Pharmacol. 2012 Apr;3(4):423-3.
H302-H31-H319-H33
P21-P24-P270-P271-P20-P302+P32-P304+P340-P330-P32+P34-P40-P01